TriPath Expanded Pap Labeling Data Claim Closes Gap With Cytyc
This article was originally published in The Gray Sheet
Executive Summary
TriPath expects narrower price differences between its SurePath and Cytyc's ThinPrep Pap test alternative over the long-term after receiving FDA sign-off on labeling that puts the tests on par for efficacy
You may also be interested in...
TriPath’s FocalPoint
Firm submits data to support approval for FocalPoint GS imaging system for automated primary cervical screening and analysis. The technology will compete with Cytyc's ThinPrep imaging system (1"The Gray Sheet" May 12, 2003, p. 27)...
TriPath’s FocalPoint
Firm submits data to support approval for FocalPoint GS imaging system for automated primary cervical screening and analysis. The technology will compete with Cytyc's ThinPrep imaging system (1"The Gray Sheet" May 12, 2003, p. 27)...
Patent Suit Or Smear Campaign? Automated Pap Firms Raise Legal Stakes
TriPath accuses Cytyc of unlawful business interference in an unfair competition/patent infringement lawsuit filed June 17